Get started
Author

Christina Verbruggen

Observed name: Verbruggen, Christina
ORCID: 0009-0004-4162-2188
Observed ORCID: 0009-0004-4162-2188
OpenAlex ID: A5032699028
Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia
2021 · Hardikkumar Jetani, Almudena Navarro-Bailón, et al. · Blood · 104
Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma
2025 · Sven Neubert, Umair Munawar, et al. · Leukemia · 6
PDF
Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy
2026 · Umair Munawar, Johanna Thurner, et al. · Leukemia · 3
PDF
Direct visualization of chimeric antigen receptors on primary human T cells using dSTORM super-resolution microscopy
2025 · Leon Gehrke, Nicole Seifert, et al. · Frontiers in Immunology · 2
PDF
PA-209 Functional Implications of FCRL5 Mutations for Cevostamab Immune Escape in Multiple Myeloma
2026 · Umair Munawar, Cecilia Bonolo de Campos, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Promoter hypomethylation drives ABCB1-mediated carfilzomib resistance in multiple myeloma
2026 · Seungbin Han, Larissa Haertle, et al. · Clinical Epigenetics · 1
Promoter hypermethylation as a reversible mechanism of resistance to GPRC5D-directed therapy in multiple myeloma
2026 · Seungbin Han, Umair Munawar, et al. · Haematologica · 1
PDF
Upregulation of BCMA expression by selinexor
2025 · Christina Verbruggen, Umair Munawar, et al. · Blood · 1
PDF
CARs are organized in nanodomains in the plasma membrane of T cells that accumulate at tumor contact sites
2023 · Christina Verbruggen, Leon Gehrke, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
PDF
PA-210 Functional Three-Dimensional Bone Marrow Organoid Provides Native-Like Environment for Multiple Myeloma Cells
2026 · Ann-Sophie Hainold, Christina Verbruggen, et al. · Clinical Lymphoma Myeloma & Leukemia
PA-436 Selinexor Treatment Upregulates BCMA and Increases Belamaf Sensitivity in BCMA-Low Cell Line Models
2026 · Christina Verbruggen, Umair Munawar, et al. · Clinical Lymphoma Myeloma & Leukemia
Abstract 3912: NQO1 as a target to overcome therapy resistance in multiple myeloma.
2026 · Seungbin Han, Christina Verbruggen, et al. · Cancer Research
Promoter hypomethylation drives ABCB1-mediated carfilzomib resistance in multiple myeloma
2026 · Han, Seungbin, Haertle, Larissa, et al. · Figshare
Additional file 2 of Promoter hypomethylation drives ABCB1-mediated carfilzomib resistance in multiple myeloma
2026 · Han, Seungbin, Haertle, Larissa, et al. · Figshare
Additional file 1 of Promoter hypomethylation drives ABCB1-mediated carfilzomib resistance in multiple myeloma
2026 · Han, Seungbin, Haertle, Larissa, et al. · Figshare
Additional file 3 of Promoter hypomethylation drives ABCB1-mediated carfilzomib resistance in multiple myeloma
2026 · Han, Seungbin, Haertle, Larissa, et al. · Figshare
Lattice light-sheet microscopy reveals patient specific responses to CD20-directed antibodies in B cell malignancies
2025 · Julia Weingart, Patrick Eiring, et al. · Blood
NQO1 modulates CD38 surface expression in multiple myeloma
2025 · Seungbin Han, Christina Verbruggen, et al. · Blood
Modeling of a hyper-inflammatory hematopoietic niche ex vivo reveals a multi-step process driving CAR T- cell associated myeloid leukemia in multiple myeloma
2025 · Max Köppel, Umair Munawar, et al. · Blood
PDF
Tumor intrinsic mechanisms leading to cevostamab resistance in multiple myeloma
2025 · Cecilia Bonolo De Campos, Umair Munawar, et al. · Blood
PDF
Melphalan-Induced Enrichment of TP53-Mutant CHIP as a Risk Factor for Subsequent CAR-T Related Myeloid Neoplasms in Multiple Myeloma
2025 · Max Köppel, Johannes Waldschmidt, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 21
Citation count: 120
H-index: 3
I10-index: 1
Year
Topic
Type